Streetbeat News

Stock Prices

KYTX

Kyverna Therapeutics shares are trading higher after the company received U.S. FDA RMAT designation for KYV-101 in the treatment of progressive myasthenia gravis.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 8:25 pm

CATX

Perspective Therapeutics shares are trading lower following the company's Q2 financial results.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 8:24 pm

OCX

Oncocyte has published a case series demonstrating the effectiveness of its VitaGraft Kidney diagnostic test in monitoring antibody-mediated rejection in kidney transplant patients treated with anti-CD38 therapy.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 8:24 pm

DDI

DoubleDown Interactive shares are trading higher after the company reported better-than-expected Q2 financial results.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 8:24 pm

GETR

Getaround (NYSE:GETR) reported Q2 2024 GAAP EPS of $(0.12), beating the $(0.18) estimate, but sales of $18.584M missed the $19.520M estimate. Sales decreased by 0.19% compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 8:24 pm

SYRS

Syros Pharmaceuticals will discontinue enrollment in the SELECT-AML-1 Phase 2 clinical trial due to disappointing interim results. The trial was evaluating a triplet regimen of tamibarotene with venetoclax and azacitidine compared to a doublet regimen in AML patients. The decision follows a futility analysis showing similar response rates between the two treatment arms.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 8:23 pm

CATX

Perspective Therapeutics (AMEX:CATX) reported Q2 EPS of $(0.17), beating the $(0.21) estimate, and sales of $526K, surpassing the $60K estimate. Despite a 50% improvement in EPS from last year, sales decreased by 10.54% year-over-year.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 8:23 pm

SRZN

Surrozen (NASDAQ:SRZN) reported a Q2 2024 adjusted EPS of $(7.99), significantly missing the analyst consensus estimate of $(2.79) by 186.38%.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 8:22 pm

BZFD

BuzzFeed shares are trading higher following Q2 earnings.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 8:21 pm

CRGX

Cargo Therapeutics (NASDAQ:CRGX) reported a Q2 2024 adjusted EPS of $(1.02), which beat the analyst consensus estimate of $(1.03) by 0.97%.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 8:19 pm